구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Palifermin (Palifermin) Swedish Orphan Biovitrum·X-Linked Combined Immunodeficiency… 48 trials·t½ 4.5 h |
|---|---|
Overview Program | Palifermin |
Overview Company | Swedish Orphan Biovitrum |
Overview Modality | CGT |
Overview Target | X-Linked Combined Immunodeficiency Disea |
Overview Indication | X-linked Severe Combined Immunodeficiency (XSCID) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | biomarkers of radiation damage, and we validated radioprotection using WR-1065, the active form of Amifostine |
PK/PD Half-life | 4.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical Safety signal | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical Result source | ClinicalTrials.gov NCT01237951 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01237951 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Palifermin (Palifermin) Swedish Orphan Biovitrum·X-Linked Combined Immunodeficiency… 48 trials·t½ 4.5 h |
|---|---|
Overview Program | Palifermin |
Overview Company | Swedish Orphan Biovitrum |
Overview Modality | CGT |
Overview Target | X-Linked Combined Immunodeficiency Disea |
Overview Indication | X-linked Severe Combined Immunodeficiency (XSCID) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | biomarkers of radiation damage, and we validated radioprotection using WR-1065, the active form of Amifostine |
PK/PD Half-life | 4.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical Safety signal | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical Result source | ClinicalTrials.gov NCT01237951 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01237951 |
추천 비교
추천 비교